Roadside Real Estate (LON: ROAD) shares have soared 172.3% to 8.85p – the highest level for six months – after it sold part of its stake in Cambridge Sleep Sciences to CGV Ventures 1 for £6m. The total stake cost £2.7m and Roadside Real Estate still owns 65%, having sold a 10% stake, so it still has to be consolidated. Management is considering selling the rest or demerging the company so that it can concentrate on its core property interests.
Evgen Pharma (LON: EVG) is acquiring Chronos Therapeutics for £900,000 in shares at 1.44p each, which means that it will no longer be a single asset company. A share issue has raised £850,000 at 1p/share and a retail offer could raise up to £1m. The share price improved 13.5% to 1.05p. Chronos Therapeutics is a pre-clinical biotech spin-out from the University of Oxford. It is developing drugs to treat central nervous system and neuropsychiatric conditions. It acquired two potential treatments from Shire Pharmaceuticals. The cash could last until 2026. The company is changing its name to TheraCryf.
Naked Wines (LON: WINE) says fourth quarter revenues are in line with expectations. Net cash has improved to £17m and the year-end figure will be at the top end of forecasts. Naked Wines is exploring refinancing options, but the current facility does not end until April 2025. The share price recovered 11.2% to 56.6p.
Payments services provider Equals Group (LON: EQLS) says that it has received an indicative offer from a consortium comprising Embedded Finance and TowerBrook Capital Partners. The strategic review continues. Trading in the first quarter to 15 March has generated revenues of £22.2m, up from £17.4m in the same period last year. The 2024 figures will be published on 16 April. The share price rose 11.4% to 56.7p.
Abingdon Health (LON: ABDX) and its partner Crest Medical are launching Boots own brand rapid self-tests in the UK. The first two are iron and vitamin D deficiency tests. The share price increased 8.82% to 9.25p.
FALLERS
Versarien (LON: VRS) raised £615,000 at 0.125p/share and this will provide further working capital. The share price declined 16.6% to 0.14925p. Earlier this year, the graphene technology developer raised £400,000 at 0.08p/share.
Three rail clients delaying orders has hit prospects for LPA Group (LON: LPA) and it is unlikely to do any better than breakeven this year – a pre-tax profit of £800,000 was previously forecast. Cavendish has reduced revenue expectations by £1.5m to £24.7m. LPA Group is already trying to reduce dependence on the rail sector and aviation continues to recover. The share price dipped 13.75 to 66p.
Semiconductors designer EnSilica (LON: ENSI) has appointed Singer as joint broker with nominated adviser Allenby. The share price fell 4.69% to 61p.
